Core Viewpoint - Nanmo Biology (688265.SH) is currently experiencing a decline in stock price, with a closing price of 47.49 yuan and a drop of 4.06%, indicating a state of being below its initial public offering price [1] Group 1: Company Overview - Nanmo Biology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an issuance of 19.49 million shares at a price of 84.62 yuan per share [1] - The stock reached a peak price of 82.00 yuan on its first trading day, which remains the highest price since its listing [1] Group 2: Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 1.649 billion yuan, with a net amount of 1.468 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 1.068 billion yuan, as the company initially aimed to raise 400 million yuan for various projects [1] - The total issuance costs amounted to 181 million yuan, with underwriting and sponsorship fees accounting for 158 million yuan [1] Group 3: Planned Use of Funds - The funds raised are intended for several projects, including the establishment of a biological research base, construction of a genetically modified model resource library, development of humanized antibody mouse models, and a drug efficacy platform based on genetically modified animal models, as well as to supplement working capital [1]

Core Insights - Guizhou Moutai has established a new biotechnology research and development company with a registered capital of 1 billion RMB [1] - The company will focus on various areas including biochemistry product R&D, fermentation process optimization, industrial enzyme development, cell technology R&D and application, and biopesticide technology R&D [1] - The new entity is jointly owned by China Guizhou Moutai Distillery (Group) Co., Ltd. and Guizhou Moutai [1]

Core Insights - Guizhou Moutai Biotech Research Co., Ltd. was established on September 19 with a registered capital of 1 billion RMB, focusing on various biotechnological research areas [1] Company Overview - The company is co-owned by China Guizhou Moutai Distillery (Group) Co., Ltd. and Guizhou Moutai Distillery Co., Ltd. [1] - The legal representative of the new company is Yang Fan [1] Industry Position - Moutai ranks third in the "2025 Kantar BrandZ Most Valuable Chinese Brands" list with a brand value of 80.023 billion USD, approximately 569.421 billion RMB, following Tencent and Alibaba [1]

Core Viewpoint - Nanmo Biology's stock price has declined significantly, currently trading at 54.64 yuan, representing a drop of 4.09%, and is in a state of loss since its IPO [1] Company Overview - Nanmo Biology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 28, 2021, with an initial stock issuance of 19.49 million shares at a price of 84.62 yuan per share [1] - The stock reached its highest price of 82.00 yuan on its first trading day [1] Fundraising and Financials - The total amount raised from the initial public offering (IPO) was 1.649 billion yuan, with a net amount of 1.468 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 1.068 billion yuan [1] - The company planned to raise 400 million yuan for various projects, including a biological research base and the development of genetically modified animal models [1] - The total issuance costs for the IPO were 181 million yuan, with underwriting fees amounting to 158 million yuan [1]

Fundraising Overview - The company raised a total of RMB 1,649,319,958.00 by issuing 19,490,900 shares at a price of RMB 84.62 per share, with a net amount of RMB 1,467,876,199.92 after deducting issuance costs [1][2] - As of June 30, 2025, the total net amount of raised funds was RMB 146,787.62 million, with RMB 146,308.22 million invested in projects and RMB 1,794.24 million in net interest income [1][2] Fund Management - The company established a management method for the raised funds, adhering to regulations to ensure proper management and usage, including a dedicated account storage system [1][2] - Six dedicated accounts for the raised funds have been closed as of June 30, 2025, indicating a complete utilization of the funds [1][2] Fund Utilization - The company did not have any idle funds or temporary use of idle funds for working capital during the reporting period [1][2] - All investment projects funded by the raised capital, including the "Gene Modification Model Resource Library" and "Humanized Antibody Mouse Model Development," have been completed [4][5] Cash Management - The company approved the use of up to RMB 80 million of excess and idle funds for cash management, allowing for cyclical use within a 12-month period starting from February 1, 2024 [1][2] Compliance and Reporting - The company confirmed that all disclosed information regarding the use of raised funds is timely, truthful, accurate, and complete, with no significant violations in fund usage [1][2]